Bruijnen et al., 2019 - Google Patents
Imaging disease activity of rheumatoid arthritis by macrophage targeting using second generation translocator protein positron emission tomography tracersBruijnen et al., 2019
View HTML- Document ID
- 1236745621345621746
- Author
- Bruijnen S
- Verweij N
- Gent Y
- Huisman M
- Windhorst A
- Kassiou M
- van de Ven P
- Lammertsma A
- Hoekstra O
- Voskuyl A
- van der Laken C
- Publication year
- Publication venue
- PLoS One
External Links
Snippet
Background Positron emission tomography (PET) imaging of macrophages using the translocator protein (TSPO) tracer (R)-[11C] PK11195 has shown the promise to image rheumatoid arthritis (RA). To further improve TSPO PET for RA imaging, second generation …
- 238000002600 positron emission tomography 0 title abstract description 71
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bruijnen et al. | Imaging disease activity of rheumatoid arthritis by macrophage targeting using second generation translocator protein positron emission tomography tracers | |
| Arnaud et al. | 18F‐fluorodeoxyglucose–positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim‐Chester disease | |
| Pien et al. | Using imaging biomarkers to accelerate drug development and clinical trials | |
| Klein et al. | Olfactory impairment is related to tau pathology and neuroinflammation in Alzheimer’s disease | |
| Yaghoubi et al. | PET imaging of herpes simplex virus type 1 thymidine kinase (HSV1-tk) or mutant HSV1-sr39tk reporter gene expression in mice and humans using [18F] FHBG | |
| Glaudemans et al. | The Use of 18F‐FDG‐PET/CT for diagnosis and treatment monitoring of inflammatory and infectious diseases | |
| Wakura et al. | Differentiation between polymyalgia rheumatica (PMR) and elderly-onset rheumatoid arthritis using 18F-fluorodeoxyglucose positron emission tomography/computed tomography: is enthesitis a new pathological lesion in PMR? | |
| Tendler et al. | Imaging with [89Zr] Zr-DFO-SC16. 56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial | |
| Saboury et al. | FDG PET/CT in Crohn’s disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity | |
| Watanabe et al. | 18F-FDG and 18F-NaF PET/CT demonstrate coupling of inflammation and accelerated bone turnover in rheumatoid arthritis | |
| Mattner et al. | Central nervous system expression and PET imaging of the translocator protein in relapsing–remitting experimental autoimmune encephalomyelitis | |
| McParland et al. | The clinical safety, biodistribution and internal radiation dosimetry of [18F] fluciclovine in healthy adult volunteers | |
| Choi et al. | In vivo imaging of mGluR5 changes during epileptogenesis using [11C] ABP688 PET in pilocarpine-induced epilepsy rat model | |
| Rosado-de-Castro et al. | Rheumatoid arthritis: Nuclear Medicine state-of-the-art imaging | |
| Bernards et al. | In vivo evaluation of inflammatory bowel disease with the aid of μPET and the translocator protein 18 kDa radioligand [18F] DPA-714 | |
| Wang et al. | Distribution features of skeletal metastases: a comparative study between pulmonary and prostate cancers | |
| Azeem et al. | Explaining slow seizure propagation with white matter tractography | |
| Caobelli et al. | Role of molecular imaging in the management of patients affected by inflammatory bowel disease: state-of-the-art | |
| Wong et al. | Characterization of [11C] RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans | |
| Brodersen et al. | FDG-PET/CT in inflammatory bowel disease: is there a future? | |
| Verweij et al. | Early prediction of treatment response in rheumatoid arthritis by quantitative macrophage PET | |
| Lan et al. | Phenomic imaging | |
| De Craemer et al. | Use of imaging in axial spondyloarthritis for diagnosis and assessment of disease remission in the year 2022 | |
| Piscopo et al. | Diagnosis, management and theragnostic approach of gastro-entero-pancreatic neuroendocrine neoplasms | |
| Watanabe et al. | The usefulness of 18F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD) |